CalciMedica Inc CALC

Healthcare

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).

NDAQ:CALC - Post by User

CalciMedica Inc

<< Previous

Bullboard Posts

Next >>

Post by johnnygoldmineron Feb 01, 2021 3:21pm

144 Views

Post# 32439046

The Shakespeare Gold Project looks VERY promising

Graycliff Exploration Identifies New Target for Drilling at Shakespeare Gold Project:
https://graycliffexploration.com/graycliff-exploration-identifies-new-target-for-drilling-at-shakespeare-gold-project/

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant